Back to News
Market Impact: 0.15
Veradermics To Review Phase 3 Study 304 Results For VDPHL01 In Male Pattern Hair Loss; Stock Up
Source: Nasdaq
Healthcare & Biotech
Veradermics announced it will review results from Part A of Study 304, a Phase 3 trial evaluating VDPHL01 in males with mild-to-moderate pattern hair loss. The available article text provides no trial results or further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Capital One, General Motors are among the stocks reporting this week with momentum. Here are the others
- Crushed tech stocks bounce — plus, new doctor survey keeps us positive on Lilly
- Merck KGaA to acquire Silence Therapeutics for $1.3 billion
- Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints
- Silence Therapeutics jumps 59% on Merck takeover
- Goldman says play defense with these stocks if you're worried about the AI bull failing